MedTrace Logo

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

NCT07024173 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-01-26

No results posted yet for this study

Summary

This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous endocrine therapy.

Conditions

Interventions

DRUG

HRS-8080 Tablet

HRS-8080 tablet orally administered.

DRUG

Fulvestrant injection

Fulvestrant injection.

DRUG

Exemestane tablets

Exemestane tablets orally administered.

DRUG

Everolimus Tablets

Everolimus tablets orally administered.

DRUG

Anastrozole Tablets

Anastrozole tablets orally administered.

DRUG

Letrozole Tablets

Letrozole tablets orally administered.

Sponsors & Collaborators

  • Shandong Suncadia Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-23
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07024173 on ClinicalTrials.gov